Cardlytics, Inc. (NASDAQ:CDLX) Receives $7.50 Consensus Target Price from Analysts

Cardlytics, Inc. (NASDAQ:CDLX - Get Free Report) has been assigned an average rating of "Reduce" from the six analysts that are covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation and five have issued a hold recommendation on the company. The average 1-year price target among brokers that have issued a report on the stock in the last year is $7.50.

Several brokerages have recently weighed in on CDLX. Craig Hallum downgraded Cardlytics from a "buy" rating to a "hold" rating in a research note on Thursday, August 8th. Northland Capmk downgraded Cardlytics from a "strong-buy" rating to a "hold" rating in a report on Friday, August 16th. Bank of America lowered shares of Cardlytics from a "neutral" rating to an "underperform" rating and lowered their target price for the company from $4.00 to $3.50 in a research note on Thursday, August 15th. Northland Securities lowered shares of Cardlytics from an "outperform" rating to a "market perform" rating and dropped their price objective for the stock from $7.00 to $5.00 in a research note on Friday, August 16th. Finally, Needham & Company LLC cut shares of Cardlytics from a "buy" rating to a "hold" rating in a report on Thursday, August 8th.

Cardlytics Trading Down 3.5 %

NASDAQ CDLX traded down $0.14 during mid-day trading on Monday, hitting $3.91. The company's stock had a trading volume of 728,000 shares, compared to its average volume of 1,368,697. The firm has a market capitalization of $194.87 million, a P/E ratio of -0.88 and a beta of 1.65. The company has a debt-to-equity ratio of 1.01, a current ratio of 1.77 and a quick ratio of 1.77. Cardlytics has a 52-week low of $2.89 and a 52-week high of $20.52. The stock's fifty day simple moving average is $6.69 and its two-hundred day simple moving average is $9.27.

Cardlytics (NASDAQ:CDLX - Get Free Report) last announced its earnings results on Wednesday, August 7th. The company reported ($0.09) EPS for the quarter, beating the consensus estimate of ($0.21) by $0.12. The business had revenue of $69.64 million for the quarter, compared to the consensus estimate of $75.39 million. Cardlytics had a negative return on equity of 17.96% and a negative net margin of 50.21%. The company's revenue was down 9.2% on a year-over-year basis. During the same period last year, the business posted ($0.57) EPS. Research analysts expect that Cardlytics will post -1.72 EPS for the current year.

Insider Activity at Cardlytics

In related news, Director Scott A. Hill acquired 40,000 shares of the firm's stock in a transaction dated Monday, August 12th. The stock was acquired at an average cost of $3.58 per share, for a total transaction of $143,200.00. Following the completion of the acquisition, the director now directly owns 40,000 shares of the company's stock, valued at approximately $143,200. The transaction was disclosed in a legal filing with the SEC, which is available at this link. In other news, Director Scott A. Hill bought 40,000 shares of the stock in a transaction that occurred on Monday, August 12th. The shares were purchased at an average cost of $3.58 per share, with a total value of $143,200.00. Following the completion of the acquisition, the director now directly owns 40,000 shares in the company, valued at $143,200. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, COO Amit Gupta sold 22,699 shares of the company's stock in a transaction dated Wednesday, July 24th. The shares were sold at an average price of $8.66, for a total transaction of $196,573.34. Following the completion of the sale, the chief operating officer now directly owns 150,569 shares of the company's stock, valued at $1,303,927.54. The disclosure for this sale can be found here. Insiders sold 86,742 shares of company stock worth $735,905 in the last 90 days. Corporate insiders own 4.40% of the company's stock.

Hedge Funds Weigh In On Cardlytics

A number of hedge funds and other institutional investors have recently modified their holdings of CDLX. Los Angeles Capital Management LLC lifted its stake in Cardlytics by 193.4% during the fourth quarter. Los Angeles Capital Management LLC now owns 78,546 shares of the company's stock valued at $723,000 after buying an additional 51,776 shares in the last quarter. Jump Financial LLC purchased a new position in shares of Cardlytics during the fourth quarter valued at $355,000. Massachusetts Financial Services Co. MA purchased a new stake in Cardlytics in the 4th quarter worth about $719,000. Brown Advisory Inc. grew its stake in Cardlytics by 1.7% during the 4th quarter. Brown Advisory Inc. now owns 199,633 shares of the company's stock valued at $1,839,000 after acquiring an additional 3,257 shares in the last quarter. Finally, Olympiad Research LP acquired a new position in shares of Cardlytics in the 4th quarter valued at about $247,000. Institutional investors and hedge funds own 68.10% of the company's stock.

About Cardlytics

Cardlytics, Inc operates an advertising platform in the United States and the United Kingdom. It offers Cardlytics platform, a proprietary native bank advertising channel that enables marketers to reach customers through their network of financial institution partners through digital channels, such as online, mobile applications, email, and various real-time notifications; and Bridg platform, a customer data platform which utilizes point-of-sale data and enables marketers to perform analytics and targeted loyalty marketing, as well as measure the impact of their marketing.